TREA

Pharmaceutical compositions of phenothiazone derivatives and analogs

Follow

Information

  • Patent Grant
  • 4859667
  • Patent Number
    4,859,667
  • Date Filed
    Wednesday, January 14, 1987
    38 years ago
  • Date Issued
    Tuesday, August 22, 1989
    35 years ago
Information
Abstract
Phenothiazone derivatives and analogs thereof, pharmaceutical compositions and methods of treatment are disclosed. These compounds are useful as inhibitors of mammalian leukotriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders and inflammation.
Description
Claims
  • 1. A pharmaceutical composition for inhibiting mammalian leukotriene biosynthesis or action containing a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
  • ______________________________________ ##STR9##wherein the substituents are:Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H SCH.sub.3 H H H H HS H H SCF.sub.3 H H H HS H H CHO H H H HS H H COCF.sub.3 H H H HS H H H H SCH.sub.3 H HS H H H H CO.sub.2 CH.sub.3 H HS H H H H CO.sub.2 H H HS H H H H CHO H HS H H H H CONH.sub.2 H HS H H H H CH.sub.2 OH H HS H H Cl H Co.sub.2 Me H HS H H Cl H CO.sub.2 H H HS H H Cl H CHO H HS H H Cl H COHN.sub.2 H HS H H Cl H CH.sub.2 OH H HS H Obenzyl Cl H H H HS H OEt Cl H F H HS H OEt Cl H CH.sub.3 H HS CH.sub.3 H Cl H CH.sub.3 H HS H CH.sub.3 Cl H CH.sub.3 H HS H OMe Br H OMe H HS H OMe Cl H OMe H HS H OEt Br H OEt H HS H OEt Cl H OEt H HS H OMe Cl H OEt H HS H OMe H H SMe H HO H OMe Br H OMe H HO H OMe Cl H OMe H HS H OMe Br H Me H HSO.sub.2 H H OH H H H HSO.sub.2 H OMe OH H OMe H HSO.sub.2 OMe OMe Me H H H HSO.sub.2 H H OMe H H H HSO.sub.2 H OMe OMe H OMe H HS OCH.sub.3 OCH.sub.3 Me H H H HS H H COCH.sub.3 H H H HS OCH.sub.3 H Br H OCH.sub.3 H HS OCH.sub.3 Cl Cl H OCH.sub.3 H HS OCH.sub.3 H Cl H OCH.sub.3 H HS H ##STR10## H H OCH.sub.3 H HS H ##STR11## Br H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 OH H OCH.sub.3 H HSO.sub.2 NHPr H NHPr H H H HSO.sub.2 ##STR12## H ##STR13## H H H HSO.sub.2 H OCH.sub.3 ##STR14## H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 Br H OCH.sub.3 H HS NHPr H NHPr H H H HS NHPr H NHPr H OCH.sub.3 H HS H NHPr NHPr H H H HS H NHPr NHPr H OCH.sub.3 H HS H OCH.sub.3 NH.sub.2 H OCH.sub.3 H HS H OCH.sub.3 NHPr H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 NHPr H OCH.sub.3 H HO OCH.sub.3 H Cl H OCH.sub.3 H HO OCH.sub.3 H Br H OCH.sub.3 H HO NHPr H NHPr H H H HSO.sub.2 H OCH.sub.3 CN H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 NHCH.sub.2 CO.sub.2 R H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 Sn-Bu H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 CH.sub.2 CO.sub.2 R H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 SO.sub.2 CH.sub.3 H OCH.sub.3 H HS H Sn-Bu H H H H HS H H Sn-Bu H H H HS H CH.sub.3 Sn-Bu H H H HS H OMe Br H CF.sub.3 H HS H OMe Br H F H HS H OMe Br H Cl H HS H OMe Br H Br H HS H OMe Br H NMe.sub.2 H HS H OMe Br H SMe H HS H OMe Br H SO.sub.2 Me H HS H OMe Br H Ph H H______________________________________ and R is H or C.sub.2 to C.sub.4 alkyl.
  • 2. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H OMe Br H OMe H HS H OMe Cl H OMe H HS H OEt Br H OEt H HS H OEt Cl H OEt H HS H OMe Cl H OEt H H.______________________________________
  • 3. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S OCH.sub.3 H Br H OCH.sub.3 H HS OCH.sub.3 Cl Cl H OCH.sub.3 H HS OCH.sub.3 H Cl H OCH.sub.3 H H.______________________________________
  • 4. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________O H OMe Br H OMe H HO H OMe Cl H OMe H H.______________________________________
  • 5. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________O OCH.sub.3 H Cl H OCH.sub.3 H HO OCH.sub.3 H Br H OCH.sub.3 H H.______________________________________
  • 6. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H SCH.sub.3 H H H H HS H H H H SCH.sub.3 H HS H OMe H H SMe H HS H S--n-Bu H H H H HS H H S--n-Bu H H H HS H CH.sub.3 S--n-Bu H H H HS H OMe Br H SMe H HS H OMe Br H SO.sub.2 Me H H.______________________________________
  • 7. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H H H H CO.sub.2 CH.sub.3 H HS H H H H CO.sub.2 H H HS H H H H CONH.sub.2 H HS H H Cl H CO.sub.2 Me H HS H H Cl H CO.sub.2 H H HS H H Cl H CONH.sub.2 H HSO.sub.2 H OCH.sub.3 CH.sub.2 CO.sub.2 R H OCH.sub.3 H H.______________________________________
  • 8. A composition of claim 1 wherein the substituents are:
  • __________________________________________________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g__________________________________________________________________________S H ##STR15## H H OCH.sub.3 H HS H ##STR16## Br H OCH.sub.3 H HSO.sub.2 ##STR17## H ##STR18## H H H HSO.sub.2 H OCH.sub.3 ##STR19## H OCH.sub.3 H H__________________________________________________________________________
  • 9. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H OCH.sub.3 NH.sub.2 H OCH.sub.3 H HS H OCH.sub.3 NHPr H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 NHCH.sub.2 CO.sub.2 R H OCH.sub.3 H H.______________________________________
  • 10. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H H H H CHO H HS H H H H CH.sub.2 OH H HS H H Cl H CHO H HS H H Cl H CH.sub.2 OH H H.______________________________________
  • 11. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S NHPr H NHPr H H H HS NHPr H NHPr H OCH.sub.3 H HS H NHPr NHPr H H H HS H NHPr NHPr H OCH.sub.3 H HO NHPr H NHPr H H H H.______________________________________
  • 12. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H OEt Cl H CH.sub.3 H HS H OMe Br H Me H HS H OMe Br H CF.sub.3 H HS H OMe Br H F H HS H OMe Br H Cl H HS H OMe Br H Br H HS H OMe Br H NMe.sub.2 H HS H OMe Br H Ph H H.______________________________________
  • 13. A composition of claim 1 wherein the substitutents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________SO.sub.2 H H OH H H H HSO.sub.2 H OMe OH H OMe H HSO.sub.2 OMe OMe Me H H H HSO.sub.2 H H OMe H H H HSO.sub.2 H OMe OMe H OMe H HSO.sub.2 NHPr H NHPr H H H HSO.sub.2 H OCH.sub.3 Br H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 NHPr H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 CN H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 S--n-Bu H OCH.sub.3 H HSO.sub.2 H OCH.sub.3 SO.sub.2 CH.sub.3 H OCH.sub.3 H H.______________________________________
  • 14. A composition of claim 1 wherein the substituents are:
  • ______________________________________Y R.sub.a R.sub.b R.sub.c R.sub.d R.sub.e R.sub.f R.sub.g______________________________________S H H CHO H H H HS H H COCF.sub.3 H H H HS H O--benzyl Cl H H H HS CH.sub.3 H Cl H CH.sub.3 H HS H CH.sub.3 Cl H CH.sub.3 H HS OCH.sub.3 OCH.sub.3 Me H H H HS H H COCH.sub.3 H H H H.______________________________________
  • 15. A composition of claim 1 wherein the compound is: 4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one.
  • 16. A composition of claim 1 wherein the compound is: 4-chloro-2,7-dimethoxy-3H-phenothiazin-3-one.
  • 17. A composition of claim 1 wherein the compound is: 4-bromo-2,7-diethoxy-3H-phenothiazin-3-one.
  • 18. A composition of claim 1 wherein the compound is: 4-chloro-2,7-diethoxy-3H-phenothiazin-3-one.
  • 19. A composition of claim 1 wherein the compound is: 4-bromo-2,7-dimethoxy-3H-phenoxazin-3-one.
  • 20. A composition of claim 1 wherein the compound is: 4-chloro-2,7-dimethoxy-3H-phenoxazin-3-one.
  • 21. A pharmaceutical composition for inhibiting mammalian luekotrine biosynthesis or action containing a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
  • ______________________________________ ##STR20##wherein the substituents are:R.sub.a R.sub.b R.sub.c R.sub.d______________________________________t-Bu t-Bu H Ht-Bu t-Bu F Ht-Bu t-Bu Me Ht-Bu t-Bu SMe Ht-Bu t-Bu H OMe______________________________________
  • 22. 2-S-glutathionyl-3H-phenothiazin-3-one; or 4-chloro-2-S-glutathionyl-phenothiazin-3-one.
  • 23. A pharmaceutical composition for inhibiting mammalian luekotrine biosynthesis or action containing a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
  • ______________________________________ ##STR21##wherein the substituents are:Y R.sub.1 R.sub.2______________________________________S, SO, or SO.sub.2 2-Cl H" 2-SCF.sub.3 H ##STR22## HS 2-t-Bu 4-t-BuS, SO, or SO.sub.2 2-CN H" H 3-CO.sub.2 Et" H 3-Cl" H H" H H" 2-Cl HS H HS 2-Cl 3-ClS 2-Br 3-BrS H HS 2-Cl HS 2-F HS 2-Br HS 2-CF.sub.3 HS 2-SCF.sub.3 HS 2-SO.sub.2 CF.sub.3 HS H 3-ClS H 3-CO.sub.2 EtS H 3-CO.sub.2 HS H 3-CNS H 3-SCF.sub.3S H HS H HS 2-Br HS 2-Cl HS 2-Cl HS 2-Cl HS 2-Cl HS 2-Cl HS H 3-CONMe.sub.2S 2-Cl HS ##STR23## HS 2-SO.sub.2 CH.sub.3 HS 2-CH.sub.2 CHCH.sub.2 HS H 3-N(CH.sub.3).sub.2S H HS 2-CH.sub.2 CO.sub.2 H HS 2-Cl HS 2-COCH.sub.3 HS H HS H HS 2-COCH.sub.3 HS H HS 4-Cl HSO H HSO.sub.2 H HSO.sub.2 4-Cl HS 2-t-Bu 9-t-BuS 2-t-Bu 7-t-BuS 2-t-Bu 7-t-BuS 2-t-Bu 7-t-Bu______________________________________R.sub.3 R.sub.4 T______________________________________H H HH H HH H HH H HH H HH H HH H H4-Cl H H4-SO.sub.2 CH.sub.3 H H4-Cl H HH H H4-Cl 7-Cl 9-Cl4-Br 7-Br 9-BrH 7-SO.sub.2 CH.sub.3 H4-SO.sub.2 CH.sub.3 H H4-Cl H HH H HH H HH H HH H HH H HH H HH H HH H HH H H4-Cl H H4-SCF.sub.3 H H4-Br H HH 8-CN HH 8-CO.sub.2 Et HH 8-CO.sub.2 H HH 8-CF.sub.3 HH 7-SO.sub.2 CH.sub.3 HH H HH 7-OCH.sub.3 HH H HH H H4-CH.sub.2 CHCH.sub.2 H HH H H4-Cl 7-SC.sub.6 H.sub.5 HH H H4-SCH.sub.2 CO.sub.2 H H HH H 7-CF.sub.34-COC.sub.6 H.sub.5 H 7-CF.sub.3H H HH 7-OCH.sub.3 H4-COC.sub.6 H.sub.5 7-OCH.sub.3 HH H HH H HH H HH H H4-OMe H H4-F H H4-Me H H4-SMe H H______________________________________
  • 24. A pharmaceutical composition for inhibiting mammalian luekotrine biosynthesis or action containing a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
  • __________________________________________________________________________ ##STR24##wherein the substituents areR.sub.1 R.sub.2 R.sub.3 R.sub.4 T__________________________________________________________________________2-N(Me).sub.2 H H H H2-SMe H H H H2-SpPAA H H H H2-C(O)CH.sub.3 H H H HH 2-SO.sub.3 H H H HH H 7-OH 6-propyl H4-Cl 1-CH.sub.2 COOH H H H4-Cl 2-CH.sub.2 COOH H H H4-OH 2-OMe 7-OMe H H4-Me 1-OMe 2-OMe H H4-Cl H 6-CH.sub.2 COOH H H4-Cl H 7-CH.sub.2 COOH H H4-Cl H 8-CH.sub.2 COOH H H4-Cl 2-N(Me).sub.2 H H H4-Cl 1-N(Me).sub.2 H H H4-Cl 2-N(Me).sub.2 7-OMe H H4-Cl 2-N(Me).sub.2 7-Cl H H4-Cl 2-SMe H H H4-Cl 2-SCH.sub.2 COOH H H H4-Cl 2-SpPAA H H H4-Cl 1-SpPAA H H H4-Cl 2-SpPAA 7-OMe H H4-Cl 2-SO.sub.3 H H H H4-Cl 2-OMe 7-Cl H H4-OMe 2-SMe H H H4-SMe H H H H4-Cl H 7/8-(CH.sub.2).sub.4 H4-Cl H 7/8-(CH.sub.2).sub.3 H4-Br 2-OMe 7-OMe H H7-NH.sub.2 H H H H2-Me 7-N(Me).sub.2 H H H7-N(Me).sub.2 H H H H1-CO.sub.2 H 4-OH 7-NMe.sub.2 H H1-Me 7-Me H H 4-Cl2-Me 7-Me H H 4-Cl1-OMe 2-OMe 7-Me H H2-OMe 7-SMe H H H4-COMe H H H H2 n-Bu H H H H4-Sn-Bu H H H H2-Me 4-Sn-Bu H H H1-OMe 2-OMe 4-Me H H1-OMe 7-OMe H H 4-Br1-OMe 7-OMe 2-Cl H 4-Cl1-OMe 7-OMe H H 4-Cl ##STR25## 7-OMe H H H ##STR26## 7-OMe H H 4-Br2-OMe 4-OH 7-OMe H H1-NHPr 4-NHPr H H H ##STR27## ##STR28## H H H4-COMe H H H H2-NHPr 4-NHPr H H H2-OME 4-CN 7-OMe H H2-OMe ##STR29## 7-OMe H H2-OMe 4-NHPr 7-OMe H H1-NHPr 4-NHPr H H H1-NHPr 4-NHPr 7-OMe H H2-NHPr 4-NHPr 7-OMe H H2-OMe 4-NH.sub.2 7-OMe H H2-OMe 4-NHPr 7-OMe H H1-OMe 4-Cl 7-OMe H H1-OMe 4-Br 7-OMe H H1-OMe 4-CN 7-OMe H H2-OMe 4-NHCH.sub.2 CO.sub.2 R 7-OMe H H2-OMe 4-Sn-Bu 7-OMe H H2-OMe 4-CH.sub.2 CO.sub.2 R 7-OMe H H2-OMe 4-SO.sub.2 Me 7-OMe H H2-Sn-Bu H H H H4-Sn-Bu H H H H2-Me 4-Sn-Bu H H H2-OMe 7-Me H H 4-Br2-OMe 7-CF.sub.3 H H 4-Br2-OMe 7-F H H 4-Br2-OMe 7-Cl H H 4-Br2-OMe 7-Br H H 4-Br2-OMe 7-NMe.sub.2 H H 4-Br2-OMe 7-SMe H H 4-Br2-OMe 7-SO.sub.2 Me H H 4-Br2-OMe 7-Ph H H 4-Br1-Me 7-Me H H 4-Cl2-NH.sub.2 H H H H__________________________________________________________________________
  • where Y is S, SO, or So.sub.2 ;
  • pPAA is paraphenylacetic acid; and
  • R is H or C.sub.1 to C.sub.4 alkyl.
  • 25. A pharmaceutical composition for inhibiting mammalian luekotrine biosynthesis or action containing a pharmaceutically acceptable carrier and an effective amount of a compound of the formula:
  • ______________________________________ ##STR30##wherein the substituents are:R.sub.1 R.sub.2 R.sub.3 R.sub.4 T______________________________________2-OMe 7-OMe H H 1-Br1-OMe 7-OMe H H 2-Br1-OMe 7-OMe H H 4-Br1-OMe 7-OMe H H 2-Cl1-OMe 7-OMe H H 4-Cl2-OMe 7-OMe H H 1-Cl2-OMe 7-OMe H H 4-Cl2-OEt 7-OEt H H 1-Br2-OEt 7-OEt H H 4-Br2-OEt 7-OEt H H 1-Cl2-OEt 7-OEt H H 4-Cl2-OMe 7-OMe 8-OMe H 1-Br2-OMe 7-OMe 8-OMe H 4-Br2-OMe 7-OMe H H 4-F2-OMe 7-OMe H H 4-CF.sub.32-OMe 7-OEt H H 4-Br2-OMe 7-OEt H H 4-Cl2-OMe 7-OEt H H 4-F2-OMe 7-OEt H H 4-CF.sub.32-OEt 7-OMe H H 4-Br2-OEt 7-OMe H H 4-Cl2-OEt 7-OMe H H 4-F2-OEt 7-OMe H H 4-CF.sub.32-OMe 7-OMe H H 4-Br______________________________________
CROSS REFERENCE TO RELATED APPLICATIONS

This is division of U.S. Ser. No. 786,257, filed Oct. 10, 1985, now U.S. Pat. No. 4,667,032 which is a continuation-in-part of application Ser. No. 559,471, filed Dec. 12, 1983, now abandoned, which is a continuation-in-part of application Ser. No. 536,487, filed Sept. 28, 1983, now abandoned, which is a continuation-in-part of application Ser. No. 459,924, filed Jan. 22, 1983, now abandoned. U.S. Pat. No. 4,667,032 (Lau et al.) is incorporated herein by reference in its entirety.

US Referenced Citations (7)
Number Name Date Kind
3536809 Applexweig Oct 1970
3598123 Zaffaroni Aug 1971
3630200 Higuchi Dec 1971
3845770 Theeuwes et al. Nov 1974
3916899 Theeuwer et al. Nov 1975
4008719 Theeuwer et al. Feb 1977
4343398 Atkinson et al. Sep 1987
Foreign Referenced Citations (3)
Number Date Country
0155623 Sep 1985 EPX
2247871 Apr 1973 DEX
48-22714 Jul 1973 JPX
Non-Patent Literature Citations (34)
Entry
Chemical Abstracts, vol. 72, No. 13, 3-30-70 P.406 (Fujisawa) (1970).
Chemical Abstracts, vol. 90, No. 9, 2-26-79 P.133 (Ghizdavu) (1979).
Chemical Abstracts, vol. 78, No. 7, 2-19-73 P.485 (Shvedov) (1973).
Chemical Abstracts, vol. 92, No. 15, 4-14-80 P.12 (Mitchell) (1980).
Journal of the Chem. Soc. Perkin Transactionsi, No. 3 (1982).
Chemical Abstracts, vol. 99, No. 9 8-29-83 P.622 (Raileanu) (1983).
Terdic et al., Rev. Roum. Chim. 13 833 (1968).
Beckett et al., Xenobiotica 8 721 (1978).
Panea et al., Rev. Roum. Chim. 25 691 (1980).
Bhargave et al., Gazz. Chim. Ital. 110 201 (1980).
Bodea et al., Ann. Chem. 698 186 (1966).
Sugita et al., Nippon Kagaku Zasshi 89 309 (1968).
Broser et al., Rev. Roum. Chim. 17 1745 (1972).
Bodea et al., Ann. Chem. 715 122 (1968).
Bodea et al., Rev. Roum. Chim. 13 971 (1968).
Terdic et al., Rev. Roum. Chim. 13 1241 (1968).
Tsujino, Tet. Lett. (10) 763 (1969).
Roseboom et al., J. Pharm. Sci. 66 1395 (1977).
Fujisawa et al., Yakugaku Zasshi 86 541 (1966).
Bodea et al., Ann. Chem. 614 171 (1958).
McRae, Can. J. Med. Sci. 31 195 (1953).
Collier et al., Can. J. Med. Sci. 30 443 (1952).
Egan et al., Adv. Prost. Throm. Leuk. Res. 11 151 (1983).
Humes et al., J. Bio. Chem. 257 1591 (1982).
Winter et al., J. Pharm. Exp. Ther. 150 165 (1965).
Collier et al., Can. J. Biochem. 43 105 (1965).
Collier et al., Can. J. Biochem. 33 773 (1955).
Bailey et al., Ann. Rpts. Med. Chem. 16 213 (1981).
Baumann et al., Prostaglandins 20 627 (1980).
Collier et al., Can. J. Res. 20B 284 (1942).
Gordon et al., J. Counc. Sci. Ind. Res. (Aust.) 13 731 (1940).
Gallagher et al., Biochem. Pharm. 14 799 (1965).
Sircar et al., Biochem. Pharm., 32, No. 1, 170-172, 1983.
Hawkey et al., Prostaglandins Leukotrienes and Medicine, 10, 405-409, 1983.
Divisions (1)
Number Date Country
Parent 786257 Oct 1985
Continuation in Parts (2)
Number Date Country
Parent 536487 Sep 1983
Parent 459924 Jan 1983